ClinicalTrials.gg
RecruitingNCT04533217Updated Dec 3, 2024

Examination of Vertebroplasty in Addition to Regular Treatment of Patients With Multiple Myeloma.

An interventional study of Vertebroplasty in Vertebral Fracture and Multiple Myeloma, sponsored by Spine Centre of Southern Denmark. Recruiting at 1 site in Denmark. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-12-03.

Sponsored by Spine Centre of Southern Denmark · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Jul 2025, 1 year 3 months ago, but the record still lists the study as recruiting.
  • Started Mar 2021; still recruiting 5 years 7 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
90
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

Patients with newly diagnosed or known multiple myeloma with newly diagnosed vertebral lesion(s) will be invited to participate in a cross-sectoral randomized controlled trial. The trial will compare two groups of patients which either receive regular medical treatment of their vertebral lesion(s) or vertebroplasty in addition to regular medical treatment. Our goal is to investigate the effectiveness of vertebroplasty and determine the role of surgical treatment in the overall treatment of patients with multiple myeloma and vertebral lesion(s).

Read the detailed description

Patients identified by the attending consultant as eligible are invited to participate. Patients who express an interest in participating will be given written and oral information on the purpose, nature and implications of study-participation.

Possible candidates will be identified at the departments of Hematology where the patients are treated for their disease. All Danish departments of Hematology will be invited to participate.

The hematologist will inform the patient of the protocol and decide if they fulfil the inclusion and exclusion criteria. If the patient wishes to participate the hematologist will fill out screening forms regarding disease stage, lines of treatment, current disease status, bisphosphonate status, and pain relief treatment. The hematologist will refer the patient to their collaborating surgical department. The surgical department will decide if the patient has contraindications for surgery and inform the patient of the risk of the procedure.

If the patient decides to participate, he or she will fill out forms regarding ODI, VAS pain score, QoL.

Before randomization, the patients will be divided into two groups, stratifying between patients with known multiple myeloma with new diagnosed spine fracture and relevant pain ≤ 3 months prior to inclusion and patients with newly diagnosed multiple myeloma with new spine fracture.

Furthermore, to ensure balanced control and intervention groups the included patients at randomization will be stratified according to 1) panned PVP of 1 vs 2-4 levels, and 2) former vertebral fractures that are not planned treated with PVP.

The patients will be randomized to either PVP treatment or conservative treatment by drawing. It is therefore not possible for patients to choose between the treatments.

Patients randomized to vertebroplasty will be referred to a facility performing vertebroplasty. Patients randomized to non-vertebroplasty will receive the departments' usual care with the option to change treatment arm after 4 weeks.

The randomization will be performed by the diagnosing clinician, but orchestrated by one individual central to the clinics. The clinics will receive sealed envelopes containing the choice of randomization equally divided between PVP and conservative treatment. When all sealed envelopes have been used for randomization, the clinics will receive new envelopes.

It will not be possible to randomize more than one patient at a time. All patients will be contacted by a research nurse on a weekly basis the first 12 weeks after enrolment and after 3 and 12 months.

All patients randomized to vertebroplasty will undergo standard operative treatment involving a standard scheduled outpatient clinical control with the surgeon 12-weeks post-operative including long-standing radiographs of the spine.

02

Conditions studied

  • Vertebral Fracture
  • Multiple Myeloma
03

In context

Spinal Fractures

144 studies on the registry are indexed under Spinal Fractures; 24 are open to participants now.

This study's planned enrollment of 90 is above the median of 80 across 85 interventional studies indexed under Spinal Fractures.

Browse Spinal Fractures studies →

Lead sponsor

Spine Centre of Southern Denmark is the lead sponsor of 22 studies on the registry; 3 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • known multiple myeloma
  • verified lesion(s) between Th6-L5
  • 4 or less fractures
  • relevant pain in 3 months or less
  • vertebroplasty can be performed in one procedure
  • VAS 5 or more

Exclusion criteria

Exclusion Criteria:

  • presence of neurologic deficit
  • psychological or psychiatric disorder hat is expected to interfere with compliance
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
90 participants (estimated)

Study arms

  • Active comparator
    Vertebroplasty

    Patients treated with vertebroplasty in addition to regular medical treatment.

    Procedure: Vertebroplasty

  • No intervention
    Regular treatment

    Patients treated with regular medical treatment.

Interventions

  • ProcedureVertebroplasty

    Injection of cement into vertebral lesion(s)

06

What researchers measure

Primary outcomes

  1. Improvement in back-specific disability

    Oswestry Disability Index v2.1 (ODI): Each section is scored on a 0-5 scale, with 5 representing the highest disability.

    Time frame: 4 weeks post-initiation of treatment

Secondary outcomes

  1. Improvement in back-specific disability

    ODI

    Time frame: Up to 12 months post-initiation of treatment

  2. Back and leg pain

    Visual Analogue Scale (VAS): 0-100 scale, with 100 representing the largest amount of pain

    Time frame: Up to 12 months post-initiation of treatment

  3. Movement, personal care, usual activities, pain/discomfort, depression/anxiety

    Self-reported questionnaire on quality of life using: - European Quality of Life - 5 Dimension (EQ-5D): 0-2 scale, with 2 representing the highest disability EQ-5D contains questions on topics contributing to the overall feeling of quality of life: * movement * personal care * usual activities (ex. occupation, family activities) * pain/discomfort * depression/anxiety.

    Time frame: Up to 12 months post-initiation of treatment

  4. Long-term stability of treated vertebra(e)

    X-rays will be used to analyze long-term stability.

    Time frame: 12 months post-initiation of treatment

  5. General health services

    General questionnaires on wether or not and to what extend the patients have been using general health services.

    Time frame: Up to 12 moths post-initiation of treatment

07

Study locations

1 of 1 sites recruiting
  • Center for Spine Surgery and Research
    Middelfart, Region Of Southern Denmark 5500, Denmark
    Recruiting
08

References and documents

Publications

  • Wickstroem LA, Carreon L, Lund T, Abildgaard N, Lorenzen MD, Andersen MO. Vertebroplasty in patients with multiple myeloma with vertebral compression fractures: protocol for a single-blind randomised controlled trial. BMJ Open. 2021 Sep 6;11(9):e045854. doi: 10.1136/bmjopen-2020-045854. PubMed 34489267 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — All data of long-term value will be stored, e.g. for use in future studies on shorter-term or long-term follow-up or reuse. Metadata and anonymized data will be available for other researchers if possible due to confidentiality and GDPR.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report, Analytic code

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2021 (actual). Primary completion is estimated for Jul 2025, 52 months after the start.

Of 36 interventional studies with no phase under Spinal Fractures, half reached primary completion within 27 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 70. This study's planned 52 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 9, 2020
First posted
Aug 31, 2020
StartActual
Mar 29, 2021
Primary completionEst.
Jul 31, 2025
CompletionEst.
Jul 31, 2026
Last update
Dec 3, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 3, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04533217
Lead sponsor
Spine Centre of Southern Denmark
Responsible party
Sponsor
First posted
Aug 31, 2020
Start date
Mar 29, 2021
Primary completion
Jul 31, 2025 (estimated)
Completion
Jul 31, 2026 (estimated)
Last update
Dec 3, 2024

Study contacts

Line Wickstroem, MD
Contact
line.adsboll.wickstrom@rsyd.dk
+4524411994
Mikkel Andersen, Professor
Contact
mikkel.andersen2@rsyd.dk
+4540344069
Mikkel Andersen, Professor
principal investigator · Centre of Spine Surgery and Research, Middelfart Hospital

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion